Crossmark

Bispecific antibodies (PD-1/CTLA-4) vs. PD-1 inhibitors with platinum-based chemotherapy±bevacizumab as first-line therapy for persistent, recurrent, or metastatic cervical cancer: a retrospective matched cohort study

Crossref DOI link: https://doi.org/10.1007/s00262-025-04204-y

Published Online: 2025-10-24

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Wang, Xin

Wu, Yaqin

Huang, Jian

Zong, Dan

He, Xia
Funding

Funding for this research was provided by:

National Natural Science Foundation of China (82172804)
License Information

Text and Data Mining valid from 2025-10-24

Version of Record valid from 2025-10-24
More Information

Article History

Received: 11 July 2025

Accepted: 14 October 2025

First Online: 24 October 2025

Declarations

:

: The authors declare no competing interests.

: This study was conducted in accordance with the Declaration of Helsinki and was approved by the Ethics Review Committee of The Affiliated Cancer Hospital of Nanjing Medical University with an approval number of KY-2025–067.

: All authors approved the final version and agreed to be accountable for all aspects of the work.

Document is current

Any future updates will be listed below